B Cell Lymphoma Clinical Trial
Official title:
Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD19 CARvac in Patients With Relapsed and/or Refractory B Cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | February 28, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Diagnosis based on the World Health Organization (WHO) 2008 2. Patients have exhausted standard therapeutic options 3. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks 4. Female must be not pregnant during the study Exclusion Criteria: 1. Prior solid organ transplantation 2. Potentially curative therapy including chemotherapy or hematopoietic cell transplant 3. Prior treatment with BCMAxCD3 or CS1xCD3 bispecific agents |
Country | Name | City | State |
---|---|---|---|
China | The General Hospital of Western Theater Command | Chengdu | |
China | Peking University Shenzhen Hospital | Shenzhen |
Lead Sponsor | Collaborator |
---|---|
iCell Gene Therapeutics | Chengdu Military General Hospital, iCAR Bio Therapeutics Ltd, Peking University Shenzhen Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with dose limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | 28 days | ||
Primary | Type of dose-limiting toxicity (DLT) | 28 days | ||
Primary | Number of participants with adverse event by severity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | 2 years | ||
Secondary | Overall Response Rate (ORR) | Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CR1), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies | 1 year | |
Secondary | Progression-free survival (PFS) | 1 year | ||
Secondary | Overall survival | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Withdrawn |
NCT02547948 -
CD19-targeting CAR T Cells for B Cell Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03258047 -
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03478514 -
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
Recruiting |
NCT06415708 -
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03307746 -
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03670888 -
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
|
Phase 1 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Recruiting |
NCT06213311 -
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04008251 -
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04637763 -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
|
Phase 1 | |
Recruiting |
NCT04782193 -
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03146533 -
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
|
Phase 1/Phase 2 | |
Recruiting |
NCT05385263 -
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
|
Phase 2 | |
Recruiting |
NCT03366324 -
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03929107 -
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
|
Phase 2 | |
Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
Recruiting |
NCT04289220 -
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
|
Phase 1 |